Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Avadel Pharmaceuticals (Nasdaq: AVDL) announced that its Compensation Committee has approved inducement awards for five new employees. The awards consist of non-statutory options to purchase 173,000 ordinary shares under the company's 2021 Inducement Plan, granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options feature a ten-year term and a four-year vesting schedule, with 25% vesting on the first anniversary of each employee's start date and additional 25% portions vesting on subsequent anniversaries through the fourth year. These grants are governed by Avadel's 2021 Inducement Plan, which was approved by the Board of Directors in November 2021.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha annunciato che il suo Comitato per la Compensazione ha approvato premi di indennità per cinque nuovi dipendenti. I premi consistono in opzioni non statutarie per l'acquisto di 173.000 azioni ordinarie nell'ambito del Piano di Indennità 2021 dell'azienda, concessi in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Le opzioni hanno un termine di dieci anni e un programma di maturazione di quattro anni, con il 25% che matura al primo anniversario della data di assunzione di ciascun dipendente e ulteriori porzioni del 25% che maturano nei successivi anniversari fino al quarto anno. Questi premi sono regolati dal Piano di Indennità 2021 di Avadel, approvato dal Consiglio di Amministrazione nel novembre 2021.
Avadel Pharmaceuticals (Nasdaq: AVDL) anunció que su Comité de Compensación ha aprobado premios de inducción para cinco nuevos empleados. Los premios consisten en opciones no estatutarias para comprar 173,000 acciones ordinarias bajo el Plan de Inducción 2021 de la compañía, otorgados de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
Las opciones tienen un plazo de diez años y un calendario de adquisición de cuatro años, con un 25% que se adquiere en el primer aniversario de la fecha de inicio de cada empleado y porciones adicionales del 25% que se adquieren en los aniversarios subsiguientes hasta el cuarto año. Estas concesiones están reguladas por el Plan de Inducción 2021 de Avadel, que fue aprobado por la Junta Directiva en noviembre de 2021.
Avadel Pharmaceuticals (Nasdaq: AVDL)는 보상위원회가 다섯 명의 신입 사원에 대한 유인 보상을 승인했다고 발표했습니다. 이 보상은 회사의 2021 유인 계획에 따라 173,000주 일반 주식을 구매할 수 있는 비법적 옵션으로 구성되어 있으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 부여됩니다.
옵션은 10년 기간을 가지며 4년의 베스팅 일정으로, 각 직원의 입사일 첫 번째 기념일에 25%가 베스팅되고, 이후 4년까지 추가로 25%씩 베스팅됩니다. 이 보상은 2021년 Avadel 유인 계획의 규정을 따르며, 이는 2021년 11월 이사회에서 승인되었습니다.
Avadel Pharmaceuticals (Nasdaq: AVDL) a annoncé que son Comité de Rémunération a approuvé des attributions d'incitation pour cinq nouveaux employés. Les attributions consistent en des options non statutaires pour acheter 173 000 actions ordinaires dans le cadre du Plan d'Incitation 2021 de la société, accordées conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Les options ont un terme de dix ans et un calendrier d'acquisition de quatre ans, avec 25% qui s'acquiert au premier anniversaire de la date de début de chaque employé et des portions supplémentaires de 25% qui s'acquièrent aux anniversaires suivants jusqu'à la quatrième année. Ces attributions sont régies par le Plan d'Incitation 2021 d'Avadel, qui a été approuvé par le Conseil d'Administration en novembre 2021.
Avadel Pharmaceuticals (Nasdaq: AVDL) gab bekannt, dass der Vergütungsausschuss Induktionsprämien für fünf neue Mitarbeiter genehmigt hat. Die Prämien bestehen aus nicht-statutären Optionen zum Kauf von 173.000 Stammaktien im Rahmen des Unternehmensplans zur Induktion 2021, die gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt werden.
Die Optionen haben eine Laufzeit von zehn Jahren und einen vierjährigen Vesting-Zeitplan, wobei 25% am ersten Jahrestag des Eintritts jedes Mitarbeiters und weitere 25% an den folgenden Jahrestagen bis zum vierten Jahr fällig werden. Diese Vergaben unterliegen dem Induktionsplan 2021 von Avadel, der im November 2021 vom Vorstand genehmigt wurde.
- Expansion of workforce with five new strategic hires
- Implementation of long-term employee retention strategy through 4-year vesting schedule
- Potential dilution of existing shareholders through 173,000 new share options
DUBLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to five (5) new employees to purchase 173,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionaq.com
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
How many shares are included in AVDL's latest inducement awards?
What is the vesting schedule for AVDL's February 2025 inducement options?
How long is the term of AVDL's February 2025 inducement options?
Under which plan were AVDL's February 2025 inducement awards granted?
